Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 14/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218025 | 0.86 | DRD2 (0.40) | DRD2DRD3ABCB1HTR1AHTR1D | |
| SCHEMBL6218026 | 0.85 | DRD2 (0.40) | DRD2DRD3ABCB1HTR1AHTR1D | |
| SCHEMBL6211706 | 0.74 | DRD2 (0.64) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6213823 | 0.73 | DRD2 (0.53) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6212310 | 0.71 | DRD2 (0.52) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6214905 | 0.70 | DRD2 (0.51) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6214883 | 0.70 | DRD2 (0.51) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6211973 | 0.69 | DRD2 (0.49) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6242842 | 0.69 | HTR1A (0.40) | DRD2DRD3HTR1AHTR1DHTR2C | |
| SCHEMBL6217301 | 0.68 | DRD2 (0.38) | DRD2DRD3HTR1AHTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222182-B1 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMA INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | DRD2 2065/4885DRD3 2125/4885ABCB1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.